Results 201 to 210 of about 4,183,748 (324)

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

REVERSE MUTATION STUDIES ON THE FORKED LOCUS IN DROSOPHILA MELANOGASTER [PDF]

, 1959
Guillaume Lefèvre, M. M. Green
openalex   +1 more source

Patterns of somatic mutation in human cancer genomes

Nature, 2007
C. Greenman, P. Stephens, Raffaella Smith, G. Dalgliesh, C. Hunter, G. Bignell, Helen R Davies, J. Teague, A. Butler, C. Stevens, S. Edkins, S. O’Meara, Imre Vastrik, Esther E. Schmidt, T. Avis, S. Barthorpe, G. Bhamra, G. Buck, Bhudipa Choudhury, J. Clements, J. Cole, E. Dicks, S. Forbes, K. Gray, Kelly Halliday, R. Harrison, K. Hills, Jonathon Hinton, A. Jenkinson, David Jones, A. Menzies, T. Mironenko, J. Perry, K. Raine, David Richardson, Rebecca Shepherd, Alexandra Small, Calli Tofts, J. Varian, T. Webb, S. West, S. Widaa, A. Yates, Daniel P Cahill, David N. Louis, P. Goldstraw, Andrew G. Nicholson, F. Brasseur, L. Looijenga, Barbara Weber, Y. Chiew, A. Defazio, Mel Greaves, Anthony R. Green, P. Campbell, E. Birney, D. Easton, G. Chenevix-Trench, M. Tan, S. K. Khoo, Bin Tean Teh, S. Yuen, Suet Y. Leung, R. Wooster, P. Futreal, Michael R. Stratton   +65 more
semanticscholar   +1 more source

A quantitative comparison of the deleteriousness of missense and nonsense mutations using the structurally resolved human protein interactome. [PDF]

Protein Sci
Su TY, Xia Y.
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

THE EFFECT OF CHRONIC GAMMA RADIATION ON THE PRODUCTION OF SOMATIC MUTATIONS IN CARNATIONS [PDF]

, 1955
Alan Richter, W. Ralph Singleton
openalex   +1 more source

B cell dysfunction in thalamus and brainstem involvement and high lactate caused by novel mutation of EARS2 gene. [PDF]

Ital J Pediatr
Wen Y, Huang Y, Zhang W, Chen P, Hu X, Xiong X, Luo L.   +6 more
europepmc   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

The evolution and convergence of mutation spectra across mammals. [PDF]

Commun Biol
Talenti A, Wilkinson T, Morrison LJ, Prendergast JGD.   +3 more
europepmc   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source